|
|
Fenotype - Based Treatment of Severe Asthma Bronchiale in the Czech Republic
Vaník, Petr ; Teřl, Milan (advisor) ; Rozborilová, Eva (referee) ; Pauk, Norbert (referee)
INTRODUCTION In recent years there has been a lot of evidence that asthma is etiopathogenetically widely heterogeneous inflammatory disease. Simultaneously with this knowledge, there are new therapeutic possibilities of severe asthma, ie. targeted biological therapy, which reflects their inflammatory heterogeneity. A prerequisite of rational indications of this treatment requires closer asthma phenotyping using available biomarkers. AIM The aim of submitted work is as follows: A) Overview of diagnostics and treatment of asthma in the world and in the Czech Republic with focus on monitoring the effect of targeted therapy of severe asthma selected on the basis of phenotyping using biomarkers. B) The work is divided into three parts. 1. In the first part it is about evaluating the effect of treatment with anti IgE antibody omalizumab in the Czech Republic since 2007. 2. In the second part, the relationship between the specific allergic profile of patients to the results of treatment with omalizumab in the Czech Republic is examined in detail. 3. The third part deals with the benefit of the periostin investigation in the selection of targeted therapy. METHODS In the first part of our work we performed a retrospective post-hoc analysis of patient data with severe refractory asthma from 10 centers in the...
|
|
|
The Role of Biomerkers Obtainet from Serum, Sputum, BALF and Lung Tissue Saamples in Assessing in Activity and Targeting Therapy of Chronic Inflammantory and Fibrotic Diseases of the Lungs and Bronchi
Kirchnerová, Olga ; Teřl, Milan (advisor) ; Koblížek, Vladimír (referee) ; Rozborilová, Eva (referee)
The role of biomarkers obtained from serum, sputum, BALF and lung tissue samples in assessing the activity and targeting therapy of chronic inflammatory and fibrotic diseases of the lungs and bronchi Introduction Chronic inflammatory and fibrotic lung and airway diseases represent a heterogeneous group of respiratory tract diseases, both with an initial inflammatory background. Crucial differences in its etiopathogenesis and location significantly influence its clinical manifestation. Considering an extensive progression in science, it is obvious that there is certain heterogeneity among inflammatory processes as well as in etiopathogenesis within the differential diagnosis. Nowadays the aim is to choose best-targetted therapy based on specific endotypes and phenotypes. Aims The aim of this study is I) to provide a comprehensive overview of biomarkers of chronic inflammatory and fibrotic lung and bronchi disorders II) to asses a diagnostic role of biomarkers in clinical practice as well as the role of biomarkers when deciding a type of phenotypically targeted therapy in patients with severe refractory asthma. Methods The work (ad II) is divided into two parts. In the first part, we correlated levels of serum biomarkers, biomarkers in induced sputum, bronchoalveolar lavage fluid and ENT findings...
|
guest ::
RSS feed.